The effectiveness of Aphrodite herbal tablets on the psychological symptoms of patients with opioid use disorder

Investigating the effectiveness of Aphrodite herbal tablets on the psychological symptoms of opioid use disorder patients undergoing methadone maintenance treatment.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N196

Enrollment

Registered

2023-02-23

Start date

2023-03-11

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction. Alcoholism and drug addiction in family

Interventions

Intervention 1: The intervention group will receive 3 Aphrodite tablets (27.66 mg each) from Gol Daru company in addition to methadone treatment. Intervention 2: The control group will receive 3 simil

Eligibility

Sex/Gender

Male

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Informed consent male gender under maintenance treatment with methadone Age between 20 and 50 years

Exclusion criteria

Exclusion criteria: Single Use of any drug or stimulant except methadone A history of taking any medication that affects the patient's sexual activity, mood and sleep Kidney and liver failure History of any glandular diseases such as high prolactin and thyroid disorders and patients whose sexual dysfunction is not caused by methadone use.

Design outcomes

Primary

Measure	Time frame
Craving. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the craving questionnaire (DDQ).;Sexual function. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Sexual Functioning Questionnaire (BFSI).;Depression. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Beck Depression Questionnaire (BDI).;Anxiety. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Beck Anxiety Questionnaire (BAI).;Sleep quality. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on Pittsburgh Sleep Quality Questionnaire (PSQI).	—

Measure

Time frame

Craving. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the craving questionnaire (DDQ).;Sexual function. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Sexual Functioning Questionnaire (BFSI).;Depression. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Beck Depression Questionnaire (BDI).;Anxiety. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on the Beck Anxiety Questionnaire (BAI).;Sleep quality. Timepoint: The beginning of the study, the end of the fourth week, the end of the eighth week and during the 2-month follow-up period of the study. Method of measurement: Based on Pittsburgh Sleep Quality Questionnaire (PSQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Amini

Kermanshah University of Medical Sciences

s.amini.md7@gmail.com+98 83 3826 1046

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026